- idUS
- Listar por autor
Listar por autor "Castro Laria, Luisa"
Mostrando ítems 1-13 de 13
-
Artículo
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients
Gómez Rodríguez, Blas José; Castro Laria, Luisa; Argüelles Arias, Federico; Castro Márquez, Cristina; Caunedo-Álvarez, Ángel; Romero Gómez, Manuel (Aran Ediciones S.A., 2017)Objective: To evaluate the efficacy and safety of a quadruple regimen (BMTO) of the “3-in-1 capsule” (containing bismuth ...
-
Artículo
Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity
Belvis Jiménez, María Inmaculada; Hergueta Delgado, Pedro; Gómez Rodríguez, Blas; Maldonado Pérez, Belén; Castro Laria, Luisa; Rodríguez Téllez, Manuel José; Argüelles Arias, Federico (Thieme, 2021)Background and study aims: Endoscopy plays an essential role in managing patients with ulcerative colitis (UC), as it ...
-
Artículo
Cut-off ranges of infliximab serum levels in Crohn’s disease in the clinical practice
Valdés Delgado, Teresa; Guerra Veloz, María Fernanda; Castro Laria, Luisa; Maldonado Pérez, Belén; Perea Amarillo, Raúl; Merino Bohórquez, Vicente; Sáez, Antonia; Caunedo Álvarez, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2020)Introduction: between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Ther apeutic ...
-
Artículo
Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?
Belvis Jiménez, María Inmaculada; Hergueta-Delgado, Pedro; Gómez Rodríguez, Blas José; Maldonado Pérez, Belén; Castro Laria, Luisa; Rodríguez Téllez, Manuel José; Argüelles Arias, Federico (Aran Ediciones S.A., 2020)Introduction: endoscopy plays an essential role in the management of patients with ulcerative colitis (UC), as it allows ...
-
Artículo
Initial experience with golimumab in clinical practice for ulcerative colitis
Castro Laria, Luisa; Argüelles Arias, Federico; García Sánchez, Valle; Benítez, José Manuel; Fernández Pérez, Ramón; Trapero Fernández, Ana María; Herrerías Gutiérrez, Juan Manuel (Aran Ediciones S.A., 2016)Background: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. Purpose: To ...
-
Artículo
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing
Argüelles Arias, Federico; Valdes Delgado, Teresa; Maldonado Pérez, Belén; González Antuña, Jaime; Castro Laria, Luisa (SAGE Publications, 2023)Background: Ustekinumab (UST) is indicated for the treatment of Crohn's disease (CD) and Ulcerative Colitis (UC). Despite ...
-
Artículo
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
Guerra Veloz, María Fernanda; Belvis Jiménez, María Inmaculada; Valdés Delgado, Teresa; Castro Laria, Luisa; Maldonado Pérez, Belén; Perea Amarillo, Raúl; Merino Bohórquez, Vicente; Caunedo Álvarez, Ángel; Vilches Arenas, Ángel; Argüelles Arias, Federico (Original Research, 2019)Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated ...
-
Artículo
Perspectiva de los pacientes con enfermedad inflamatoria intestinal durante la pandemia COVID-19: resultados Encuesta ACCU
Fernández Álvarez, Paula; Belvis Jiménez, María Inmaculada; Maldonado Pérez, Belén; Castro Laria, Luisa; Caunedo Álvarez, Ángel; Rodríguez de los Ríos, José Luis; Argüelles Arias, Federico (Arán Ediciones, S.L., 2021)Introducción y objetivos: la pandemia por el SARS-CoV-2 ha obligado a un cambio sustancial en la atención a los pacien- tes ...
-
Artículo
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori
Moreno Márquez, Carolina; Fernández Álvarez, Paula; Castro Laria, Luisa; Argüelles Arias, Federico; Caunedo Álvarez, Ángel; Gómez Rodríguez, Blas José (Aran Ediciones S.A., 2022)Introduction: the primary goal of this study was to com pare gastrointestinal symptom reduction in patients on ...
-
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
Guerra Veloz, María Fernanda; Vázquez Morón, Juan María; Belvis Jiménez, María Inmaculada; Pallares Manrique, Héctor; Valdés Delgado, Teresa; Castro Laria, Luisa; Merino Bohórquez, Vicente; Vilches Arenas, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2018)Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of ...
-
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Argüelles Arias, Federico; Guerra Veloz, María Fernanda; Perea Amarillo, Raúl; Vilches Arenas, Ángel; Castro Laria, Luisa; Maldonado Pérez, Belén; Merino Bohórquez, Vicente; Romero Gómez, Manuel (Lippincott Williams & Wilkins, 2017)Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ...
-
Artículo
Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response
Lorenzo González, Laura; Valdés Delgado, Teresa; Vázquez Morón, Juan María; Castro Laria, Luisa; Leo Carnerero, Eduardo; Maldonado Pérez, María Belén; Sánchez Capilla, Damián; Pallarés Manrique, Héctor; Sáez Díaz, Antonia; Argüelles Arias, Federico (Aran Ediciones S.A., 2022)Background: ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the ...
-
Artículo
Vedolizumab response in inflammatory bowel disease. Two years of follow-up
Belvis Jiménez, María Inmaculada; Pino Bellido, Pilar del; Castro Laria, Luisa; Maldonado Pérez, María Belén; Sáez Díaz, Antonia; Caunedo Álvarez, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2020)Background: vedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and ...